- |||||||||| Trial completion date, Trial termination: Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD (clinicaltrials.gov) - Jan 25, 2019
P3, N=151, Terminated, Trial completion date: Oct 2015 --> Sep 2018 Trial completion date: Mar 2023 --> Sep 2018 | Active, not recruiting --> Terminated; VTL-308 failed to meet its primary endpoint, all follow up studies were terminated
- |||||||||| Enrollment closed, Trial completion date, Trial primary completion date: Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/ AILD (clinicaltrials.gov) - Jun 12, 2018
P3, N=151, Active, not recruiting, Trial completion date: Mar 2023 --> Sep 2018 | Active, not recruiting --> Terminated; VTL-308 failed to meet its primary endpoint, all follow up studies were terminated Recruiting --> Active, not recruiting | Trial completion date: Mar 2018 --> Mar 2023 | Trial primary completion date: Dec 2017 --> Mar 2018
- |||||||||| emricasan (IDN 6556) / Histogen, Amerimmune
Trial primary completion date: Study of IDN-6556 in Patients With Severe AH and Contradictions to Steroid Therapy (clinicaltrials.gov) - Sep 25, 2015 P2, N=5, Terminated, N=150 --> 18 | Recruiting --> Terminated | Trial primary completion date: May 2016 --> Oct 2015; Due to results from the VTI-208 study, the ELAD plan is being re-evaluated. Trial primary completion date: Nov 2014 --> Aug 2015
- |||||||||| emricasan (IDN 6556) / Histogen, Amerimmune
Enrollment change, Trial termination: Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF (clinicaltrials.gov) - Apr 30, 2015 P2, N=23, Terminated, Trial primary completion date: Jun 2015 --> Jun 2016 N=60 --> 23 | Active, not recruiting --> Terminated; Data needs met
- |||||||||| emricasan (IDN 6556) / Histogen, Amerimmune
Enrollment change, Trial termination, Trial primary completion date: Study of IDN-6556 in Patients With Severe AH and Contradictions to Steroid Therapy (clinicaltrials.gov) - Feb 12, 2015 P2, N=5, Terminated, Trial primary completion date: Mar 2015 --> Jun 2015 N=60 --> 5 | Recruiting --> Terminated | Trial primary completion date: Jul 2017 --> Apr 2015; Emerging data indicated 25mg may not be adequate in very severe hepatic impairment subjects despite higher exposures and that additional dose-ranging was needed
- |||||||||| emricasan (IDN 6556) / Histogen, Amerimmune
Enrollment closed, Trial primary completion date: Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF (clinicaltrials.gov) - Oct 2, 2014 P2, N=60, Active, not recruiting, N=120 --> 150 | Trial primary completion date: Feb 2015 --> May 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Nov 2014
- |||||||||| Trial suspension: SETH-HA: Liver Transplantation in Alcoholic Hepatitis (clinicaltrials.gov) - Jun 1, 2014
P=N/A, N=40, Suspended, Recruiting --> Active, not recruiting | Trial primary completion date: Aug 2014 --> Nov 2014 Not yet recruiting --> Suspended
|